Abstract:OBJECTIVE:To evaluate the impact of histology on efficacy of pemetrexed in Chinese non-small cell lung cancer (NSCLC) patients. This report summarized the results of two clinical trials of pemetrexed in Chinese patients with advanced NSCLC in 2nd line setting and maintenance setting after 1st line (JMID study and Chinese subgroup from JMEN study) treatment.METHODS:For the Chinese JMID study (second-line), Chinese patients with locally advanced or metastatic (stage IIIA, IIIB or IV) NSCLC who had prior chemotherapy were enrolled. The study was designed to investigate the noninferiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) to docetaxel (75 mg/m(2), day 1 of each 21-day cycle) in terms of overall survival (OS). For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint.RESULTS:In JMID study, the OS was similar between the pemetrexed group (Pem group) and docetaxel group (Doc group). Retrospective histological subtype analysis showed survival benefits (both OS and PFS) numerically of non-squamous patients over squamous patients in the Pem group (OS: HR 0.74, 95% CI 0.45-1.21, P = 0.2267, median 11.7 vs. 9.7 months; PFS: HR 0.77, 95% CI 0.44-1.34, P = 0.3585, median 3.0 vs. 1.7 months). In the Chinese subgroup of JMEN study, the median PFS in the Pem group for squamous and nonsquamous patients was 4.2 and 1.5 months for squamous patients, the median OS in the Pem group for squamous and nonsquamous patients was 22.5 and 6.2 months for squamous patients. In JMEN China subgroup analysis, the HR on histology was not analyzed due to the small sample size. In terms of safety profile, drug-related grade 3 or 4 hematological toxicities (leukocytopenia and neutropenia) events occurring after second-line treatment were significantly lower in the Pem group than in the Doc group (both P < 0.001). Similarly in patients receiving pemetrexed maintenance after first-line treatment, incidences of toxicity events were low.CONCLUSIONS:Consistent with global results, in Chinese NSCLC patients, histology has an impact on the efficacy of pemetrexed, in which non-squamous histology predicts a positive outcome for patients treated with pemetrexed. In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. Based on consistent Chinese data from the two studies, pemetrexed is recommended as a standard chemotherapy regime in both second-line and maintenance setting after first-line treatment for Chinese non-squamous NSCLC patients.

Estimating the Value of a Patient Assistance Program for Pemetrexed As a Maintenance Therapy for NSCLC in China

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program

Cost-Effectiveness of Continuation Maintenance Pemetrexed after Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Estimates from the Perspective of the Chinese Health Care System

Cost-effectiveness Analysis of Pembrolizumab Plus Standard Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Metastatic Non-Squamous Non-Small-cell Lung Cancer in China.

OP11 Cost-Effectiveness of Atezolizumab Plus Chemotherapy As A First-Line Treatment for Metastatic Non-Squamous Non-Small Cell Lung Cancer

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Cost-Effectiveness Analysis of EGFR Mutation Testing and Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in China

Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

[Impact of Histology on Efficacy of Pemetrexed: Pemetrexed in Second-Line Setting and As Maintenance Therapy after First-Line Treatment in Chinese Patients with Advanced NSCLC].

Cost-effectiveness Evaluation Based on Two Models of First-Line Atezolizumab Monotherapy and Chemotherapy for Advanced Non-Small Cell Lung Cancer with High-Pdl1 Expression

Efficacy and Safety of Pemetrexed Maintenance Therapy Versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: an Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial

Cost-effectiveness of Camrelizumab Plus Chemotherapy Vs. Chemotherapy in the First-Line Treatment of Non-Squamous NSCLC: Evidence from China

Supplementary Material For: A Cost-Effectiveness Analysis of Docetaxel Versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.

Cost-effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-cell Lung Cancer in China

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients with PD-L1 Expression ≥ 50%

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy As First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Cost-effectiveness of Gefitinib, Icotinib, and Pemetrexed-Based Chemotherapy As First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China